Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2014 · 10-Q
Revenue$22.69M$22.69M+1,704.9% vs Q3 2013 Net Income-$2.37M-$2.37MN/M vs Q3 2013 EPS Diluted-$0.06-$0.06N/M vs Q3 2013 Operating Income-$736,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,808,000N/M Margins · derivedOperating margin-3.2%+1363.1 pt vs Q3 2013
Net margin-10.5%+1906.5 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 12, 2014 · 43 d after period end